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Physical Activity Survey found that children 9-13y consumed on average
19.2 mg caffeine per day. However, little is known about caffeine con-
sumption and its impact on sleep in children. This study assessed caffeine
consumption and sleep in school aged children.
Methods: Children aged 8-12 y (10.7 ± 1.3 y, 49% male) were recruited
through South Australian schools and the community for a retrospective,
cross sectional study. Demographics, caffeine intake (a Food Frequency
Questionnaire), and daytime sleepiness (Paediatric Daytime Sleepiness
Scale) were obtained via child and parent report.
Results: Data from 230 children demonstrated daily caffeine intake
ranged between 0e64.1 mg (7.8 ± 11.7 mg). Gender did not impact
caffeine intake (p ¼ 0.97). 74% of 8 year olds consumed caffeine (8.0 ±
10.5 mg), 78% of 9 years olds (8.3 ± 9.6 mg), 72% of 10 year olds (10.1 ±
13.5 mg), 83% of 11 year olds (9.7 ± 13.4 mg) and 87% of 12 year olds
(12.6 ± 13.2 mg). Twenty-ﬁve percent (n ¼ 58) of the sample consumed
between 11.1mg (~Standard chocolate bar) and 64.1 mg (~one small
latte) of caffeine/day. Daily caffeine consumption had a signiﬁcant
relationship with age (r ¼ 0.14, p ¼ 0.03) and daytime sleepiness (r ¼
0.14, p ¼ 0.03). Children who were in the top 25% of caffeine con-
sumption had signiﬁcantly higher daytime sleepiness compared to the
remaining 75% of the sample (p ¼ 0.05).
Conclusions: These ﬁndings show that majority of children aged 8e12 y
consume caffeine. The study also shows a signiﬁcant relationship between
caffeine intake and daytime sleepiness in children, with greater caffeine
consumption associated with more daytime sleepiness.
Funding source(s): N/A.
THE METABOLISM OF DIETARY ARACHIDONIC AND EICOSAPENTAENOIC
ACIDS IN ATLANTIC SALMON AS AFFECTED BY ENVIRONMENTAL
TEMPERATURE
G. Turchini, F. Norambuena. Deakin University, VIC, Australia
E-mail address: giovanni.turchini@deakin.edu.au (G. Turchini)Background/Aims: Aquaculture is encountering sub-optimal conditions
due to changing environments. Simultaneously, shortages in marine
oils are resulting in a reduction of dietary long chain-PUFA. The effects
of water temperature and dietary arachidonic acid (ARA):EPA ratios on
the regulation of fatty acid (FA) metabolism in salmon were
investigated.
Methods: Atlantic salmon kept at optimal (10 C) and elevated (20 C)
temperature were fed one of three experimental diets. The diets had
identical FA composition with the exception of the EPA/ARA ratio,
varying from 2.4 to 0.1. The FA metabolism was assessed via the whole-
body-fatty-acid-method and selected genes expression was quantiﬁed
by qPCR.
Results: The higher temperature showed an increase in the total FA b-
oxidation (from 1,645.3 to 814.5 nmol/g/day at 20C or 10 C, respectively).
At both temperatures, the b-oxidation of SFA andMUFAwas lower in group
with highest dietary EPA supply. The higher temperature showed a
reduction in the activity and gene transcription of FA desaturases (D6fad
and D5fad) and elongase Elovl2, whereas elongase Elovl5 was not affected.
The metabolic fate of ARA was affected by temperature and dietary
treatment. Whereas, in ﬁsh held at 20 C, the metabolic fate of dietary EPA
was identical for all three treatments.
Conclusions: Temperature plays remarkable effects on EPA and ARA
metabolism. Increased dietary ARA supply, relative to EPA, is beneﬁcial in
ﬁsh held at elevated water temperatures. These ﬁndings contribute to-
wards the formulation of novel functional aquaculture diets.
Funding source(s): ARC Discovery Project.
CONCURRENT SESSION 6: LIPIDS.
ROSUVASTATIN, LYCOPENE AND OMEGA-3 FATTY ACIDS: A POTENTIAL
TREATMENT FOR SYSTEMIC INFLAMMATION IN COPD
E.J. Williams 1,2, K.J. Baines 1,2, J.M. Smart 1,2, P.G. Gibson 1,2, L.G.
Wood 1,2. 1Centre for Asthma and Respiratory Diseases, Hunter Medical
Research Institute, Newcastle, NSW, Australia; 2University of Newcastle,NSW, Australia
E-mail address: evan.j.williams@uon.edu.au (E.J. Williams)
Background/Aims: Chronic Obstructive Pulmonary Disease (COPD) is
characterized by lung and airway inﬂammation, resulting in loss of lung
function. Systemic inﬂammation is a feature of COPD contributing to many
associated co-morbidities. Statins, omega-3 fatty acids (DHA and EPA) and
lycopene have been shown to decrease systemic inﬂammation; this
combination has not been studied previously. The aim of this study was to
identify changes in systemic and airway inﬂammation induced by statins
and/or DHA, EPA and lycopene in COPD.
Methods: COPD patients (n ¼ 11) received rosuvastatin (20 mg/day) for 4
weeks, then a combination of rosuvastatin (20 mg/day), DHA and EPA (1.5
g/day) and lycomato (45 mg/day) for 8 weeks. Blood and sputum were
collected and lung function measured by spirometry at baseline, week 4
and 12. Plasma C-reactive protein (CRP) and IL-6 were measured using
ELISA; peripheral blood gene expression was measured using nCounter™
GX Human Inﬂammation Kit 2.
Results: Following interventions, clinical characteristics were unchanged.
Plasma IL-6 and CRP were unchanged by intervention, sputum neutrophils
were increased andmacrophages decreased by rosuvastatin (p¼ 0.020 and
p ¼ 0.015; respectively). Rosuvastatin increased LTB4R and decreased
CXCL10 and AGER blood gene expression. When lycopene and omega-3
fatty acids were added, LTB4R decreased and CXCL10 decreased to basal
levels, whilst combined intervention increased ALOX15 blood gene
expression.
Conclusions: This study shows rosuvastatin, omega-3 fatty acids and
lycopene may have anti-inﬂammatory effects systemically, but rosuvas-
tatin may increase airway neutrophils, which would be undesirable in
COPD, warranting further investigation.
Funding source(s): NHMRC, Centre for Clinical Research Excellence.
POLYUNSATURATED FATTY ACID FOOD FREQUENCY QUESTIONNAIRE
VALID-ATION IN PEOPLE WITH END STAGE RENAL DISEASE ON
DIALYSIS
L. Roach 1, K. Russell 2, K. Lambert 3, J. Holt 3, B. Meyer 1. 1 School of Medicine,
University of Wollongong, NSW, Australia; 2Charles Sturt University, Wagga
Wagga, NSW, Australia; 3Renal Unit, Wollongong Hospital, NSW, Australia
E-mail address: lar966@uowmail.edu.au (L. Roach)
Background/Aims: People on dialysis have a high risk of cardiovascular
disease. PUFA in particular omega-3 fatty acids are of interest in this
population due to their cardioprotective properties. The PUFA food
frequency questionnaire (FFQ) is a validated tool to measure PUFA
intake in healthy populations, but has yet to be validated in a diseased
population. The aim of this study is to validate the PUFA FFQ using the
method of triads in a population of end stage renal failure patients on
dialysis.
Methods: Participants (n ¼ 32) completed the PUFA FFQ and multiple 24
hour recalls, non-fasting blood samples were taken (n ¼ 29) for erythro-
cyte fatty acid analysis. The triangular relationship between the PUFA FFQ,
24 hour recalls and the biomarker were assessed using the method of
triads, which calculated validity coefﬁcients for PUFA. Agreement between
the two dietary methods were also assessed using Bland-Altman plots and
classiﬁcation by quintiles.
Results: The PUFA FFQ was a valid measure of all PUFA except for doco-
sapentaenoic acid (DPA) and arachidonic acid (AA). Strong validity co-
efﬁcients were found for long chain omega-3 fatty acids eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) of 0.914 (95% CI: 0.665, 0.997)
and 0.889 (95% CI: 0.706, 0.994) respectively. Bland Altman plots showed a
good level of agreement between the PUFA FFQ and the 24 hour recalls as
approximately 95% of observations were between the levels of agreement.
Conclusions: The PUFA FFQ is a valid tool for assessing PUFA intake in a
population of dialysis patients.
Funding source(s): N/A.
FAT TYPE IN PHYTOSTEROL SPREADS INFLUENCE THEIR CHOLESTEROL-
LOWERING POTENTIAL: A SYSTEMATIC REVIEW AND META-ANALYSIS
OF RCTS
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Background/Aims: Dietary supplementation with 2.0-2.5 g per day of
phytosterols (PS) is well known to reduce LDL cholesterol levels by 10-15%.
The most common form of PS-enriched food products are the fat
(margarine) spreads. The predominant fat used in these spreads is either
soybean/sunﬂower (SS) or rapeseed/canola (RC) oils. This study aimed to
investigate whether the carrier fat is a determinant of the hypo-
cholesterolaemic effects of PS-enriched spreads.
Methods: Four databases (Medline, Cochrane, Embase, CINAHL) were
searched using relevant search terms. Published RCTs from 1990 investi-
gating the effects of dietary PS intervention ( 1.5 g per day) on plasma
total (TC) and LDL cholesterol were included. Duplicates (n ¼ 1177) were
removed. Methodological quality of articles was assessed by two inde-
pendent researchers using the Academy of Nutrition and Dietetics’ Quality
Criteria Checklist. Data extracted using standardised tool (PS dose, dura-
tion, sample size, spread fat type and lipids). Studies grouped by fat type;
meta-analysis conducted.
Results: Of 1484 screened abstracts, a total of 16 RCTs (n¼ 6 SS; n ¼ 10 RC)
were included. 14 studies involved mild to moderate hyper-
cholesterolaemic subjects, and two studies involved normocholester-
olaemic subjects. TC signiﬁcantly reduced by 6% and 8% in SS and RC
studies (respectively; p < 0.05 for both). LDL signiﬁcantly reduced by 8%
and 11% in SS and RC studies (respectively; p < 0.05 for both).
Conclusions: The fat type used for the delivery of PS in fat spreads may be
a determinant of the cholesterol-lowering property of PS.
Funding source(s): N/A.
THE EFFECT OF DIETARY FAT CONSUMPTION ANDWEIGHT LOSS ON FAT
TASTE
L.P. Newman 1, D.P. Bolhuis 1, S.J. Torres 2, R.S.J. Keast 1. 1Centre for Advanced
Sensory Science, School of Exercise and Nutrition Sciences, Deakin University,
VIC, Australia; 2Centre for Physical Activity and Nutrition Research, School of
Exercise and Nutrition Sciences, Deakin University, VIC, Australia
E-mail address: l.newman@deakin.edu.au (L.P. Newman)
Background/Aims: Fat taste sensitivity is impaired in obese individuals
and is associated with consumption of dietary fat. Increasing sensitivity to
fats throughout the alimentary canal may be an effective strategy to ach-
ieve sustainable weight loss. This study assessed the effect of a six-week
low-fat diet or portion control diet matched for weight loss on fat taste
thresholds, fat perception and food preference in overweight or obese
people.
Methods: Participants (n ¼ 53; BMI 31.0 ± 0.7 kg/m2) were randomised to
a six-week low-fat diet (25% total fat) or portion control diet (33% total fat).
Anthropometry, fat taste thresholds (lowest detectable fat concentration),
fat perception (discrimination ability) and preference were assessed at
baseline and week six.
Results: Consumption of a low-fat diet (n ¼ 26) and portion control diet (n
¼ 27) reduced participant’s weight (p < 0.001) with no signiﬁcant differ-
ences between groups. Both diets resulted in a decrease in fat taste
thresholds (increased fat taste sensitivity) (p ¼ 0.014), with a trend for a
stronger effect in the low-fat diet versus the portion control diet (p ¼
0.060). The ability to perceive fat in foods was increased in the low-fat diet
group only (p ¼ 0.017), however preference for the level of fat in foods did
not change.
Conclusions: A low-fat and portion control diet both increased fat taste
sensitivity in overweight or obese people, with the strongest effect in the
low-fat diet group. This increase in fat taste sensitivity may help induce a
healthy satiety response to dietary fat and in turn reduce excess energy
intake and weight gain.
Funding source(s): NHMRC and Deakin University.IS FISH OIL EFFECTIVE AS AN ADJUNCT THERAPY FOR NON-SURGICAL
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Background/Aims: Long chain omega-3 poly-unsaturated fatty acids (LCn-
3PUFA) are beneﬁcial for several inﬂammatory conditions. We evaluated
the clinical efﬁcacy of ﬁsh oil supplementation as an adjunct to standard
therapy for advanced chronic periodontitis.
Methods: Participants with advanced chronic periodontitis (10M/23F,
mean age 52 ± 10 years) were randomised to consume ﬁsh oil capsules
providing 1884 mg LCn-3PUFA/day (n ¼ 23) or placebo capsules providing
2000 mg soy oil/day (n ¼ 10) for 4 months in a randomised parallel study
design. Patients were assessed at baseline and after 4 months for clinical
outcomes, viz. probing pocket depth (PPD) and clinical attachment (CAL),
and fasting blood samples were assessed for LCn-3PUFA erythrocyte
content and plasma C reactive protein (CRP). In addition dietary intake of
LCn-3PUFA was assessed using a validated food frequency questionnaire.
Results: Erythrocyte LCn-3PUFA increased by 50% in the ﬁsh oil supple-
mented group with no change in the placebo group. There were no
changes in dietary consumption of LCn-3PUFA in either group indicating
good compliance with supplementation. Both groups had improvements
in clinical outcomes, with signiﬁcant reductions in PPD and CAL gain.
There was no signiﬁcant difference between groups in the percentage of
sites that had  2 mm gain of CAL (p ¼ 0.229) or reduction in PPD (p ¼
0.264) after 4 months and there was no signiﬁcant change in plasma CRP
levels in either group.
Conclusions: Whilst periodontal treatment was effective in all partici-
pants, no additional beneﬁt was observed with ﬁsh oil supplementation
for 4 months.
Funding source(s): Australian Dental Research Foundation grants; Nova-
sel Australia LTD donated the capsules.
CONCURRENT SESSION 7: OBESITY.
EVALUATION OF A WEIGHT-LOSS INTERVENTION IN OBESE CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) PARTICIPANTS
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Background/Aims: There is a paucity of evidence to guide clinicians about
appropriate nutritional management strategies for obese Chronic
Obstructive Pulmonary Disease (COPD) patients. This study aimed to a)
characterise nutritional biomarkers in obese COPD participants, and b)
evaluate changes in nutritional biomarkers following a weight-loss inter-
vention in obese COPD participants.
Methods: Nutritional biomarkers, plasma fatty acids (FAs) and caroten-
oids, were analysed using GC and HPLC respectively and compared in 10
healthy weight and 39 obese COPD adults. Of the obese COPD participants,
28 completed a weight-loss intervention. Changes in diet quality were
examined using 4-day food records and nutritional biomarkers. Predictors
of weight-loss were examined using multiple linear regression.
Results: Therewas a trend towards higher total plasma FAs (p¼ 0.052) and
carotenoids (p ¼ 0.094) in the obese group. Following the weight-loss
intervention, signiﬁcant decreases in total (p ¼ 0.009) and saturated (p ¼
0.037) fat intake, and corresponding decreases in total (p ¼ 0.007) and
saturated (p ¼ 0.003) plasma FAs were observed. There was a trend to-
wards higher total plasma carotenoids post-intervention (p ¼ 0.078), with
